Resources

Abstracts or full text articles can be found for the references listed below by going to http://www.ncbi.nlm.nih.gov/pubmed

Selye H: The dermatologic implications of stress and calciphylaxis. J Invest Dermatol 1962; 39: 259-75.

Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.

Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart
valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-7.

Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32: 384-91.

Llach F, Velasquez Forero F: Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001; 38(5 Suppl 5): S20-33.

Block GA: Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 2001; 10: 741-7.

Case Report. New Engl J Med 2001; 345: 1119-24.
Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G: Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64:1118-29.

Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60: 324-32.

Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61 :2210-7.

Korkmaz C, Dundar E, Zubaroglu I: Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency. Clin Rheumatol 2002; 21: 66-

Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A: Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol 2002; 15: 676-80.

Schäfer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-66

Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-33.

Murshed M, Schinke T, McKee MD, Karsenty G: Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165: 625-30.

Cichone JS, Petronis JB, Embert CD, Spector DA: Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43:1104-8.

Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, van Diest R, Appels A, Reutelingsperger CP, Cleutjens JP, Vermeer C: Novel conformation-specific antibodies against matrix g-carboxyglutamic acid (Gla) protein – undercarboxylated matrix Gla protein as marker for vascular calcification. Atheroscler Thromb Vasc Biol 2005; 25: 1629-33.

Ketteler M: Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 2005; 14: 337-42

Stenvinkel P, Ketteler M, Johnson R, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M: Interleukin-10, IL-6 and TNF-a in end-stage renal disease – the good, the bad and the ugly. Kidney Int 2005; 67:1216-33.

Duffy A, Schurr M, Warner T, Chen H: Long-term outcomes in patients with calciphylaxis from hyperparathyroidism.
Ann Surg Oncol 2006; 13: 96-102.

Ketteler M, Schlieper G, Floege J: Calcification and cardiovascular health: new insights into an old phenomenon.
Hypertension 2006; 47: 1027-34.

Velasco N, MacGregor MS, Innes A, MacKay IG: Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant 2006; 21: 1999-2004.

Shiraishi N, Kitamura K, Miyoshi T, Adachi M, Kohda Y, Nonoguchi H, Misumi S, Maekawa Y, Murayama T, Tomita
M, Tomita K: Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006; 48: 151-4.

Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, Demey JG, Vermeer C: Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109:2823-31.

Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW: Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007; 72:202-7.